A CE marked coronary imaging system is the only device available in both the United States and Europe for the detection of the plaques known to complicate stenting and believed to be the reason for most heart attacks.

InfraReDx, Inc. (Burlington, MA, USA), a medical device company providing intelligent cardiovascular diagnostic imaging technologies, reported that it has received CE Marking approval to begin commercialization of the LipiScan IVUS (intravascular ultrasound) coronary imaging system throughout Europe.

"Receipt of the CE Mark for the LipiScan IVUS system is an important regulatory milestone for InfraReDx as we advance our global commercialization strategy to make this novel product available to physicians worldwide," said Donald Southard, president and chief executive officer of InfraReDx. "With the US launch of the system well underway, we are already receiving tremendous interest from physicians in Europe and are in active discussions with prospective distributors of the product. We are currently finalizing our European marketing plan and expect to launch the LipiScan IVUS in select countries in the coming months."

The LipiScan IVUS coronary imaging system received US Food and Drug Administration (FDA) approval in June 2010. The system includes the world's first and only cardiac catheter to combine IVUS and near infrared (NIR) spectroscopy to help cardiologists identify and characterize lipid core coronary plaques. In a single catheter pullback, the LipiScan IVUS provides physicians with a traditional IVUS image that clearly displays key structural parameters of the lesion, including its location, length, and degree of stenosis, in addition to confirming correct stent placement. At the same time, the system performs spectroscopic analysis of optical data to produce a Chemogram map that indicates the location of lipid core plaques and quantifies their lipid core burden. Integrating and coregistering the Chemogram with IVUS provides critical information to interventional cardiologists during the cardiac catheterization procedure.

"The LipiScan IVUS system is an important new intravascular imaging tool that will be of immediate value to interventional cardiologists for the diagnosis and management of their patients," said Patrick W. Serruys, MD, PhD, professor of interventional cardiology at the Thoraxcenter, Erasmus University Hospital (Rotterdam, The Netherlands). This impressive multimodality system provides an IVUS image of the vessel while simultaneously performing spectroscopic analysis for the accurate and immediate detection of lipid core plaques demonstrated to complicate stenting and suspected to cause most heart attacks. The Thoraxcenter is proud of its association with InfraReDx and the role we have played in the development of the LipiScan IVUS system and imaging catheter."

 

Guangzhou Jia Yu medical equipment Limited